Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Low-dose naltrexone (LDN) is used off-label for the conditions described herein. Patients should consult a qualified healthcare professional before initiating, modifying, or discontinuing any medication. The author and publisher disclaim any liability arising from the use of this information.

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine |

Integrative & Functional Medicine Physician

www.directintegrativecare.com

Introduction

Low-dose naltrexone (LDN) has emerged as one of the most intriguing repurposed medications in modern integrative medicine. Originally approved by the FDA in 1984 at 50 mg for opioid dependence and later for alcohol use disorder, naltrexone in low doses (typically 1–5 mg/day) has demonstrated immunomodulatory, anti-inflammatory, and analgesic properties that have captured the attention of clinicians and patients alike [1, 2]. Despite a growing body of clinical evidence, many practical questions remain about how to best prescribe, store, and individualize LDN therapy. This article distills clinical experience and peer-reviewed evidence into actionable guidance for both practitioners and patients.

1. LDN Storage and Stability

Naltrexone hydrochloride is a chemically robust molecule under standard conditions. The primary threats to its stability are heat, ultraviolet light, and extremes of pH—not cold temperatures or routine handling. This is a reassuring profile for patients who worry about accidental exposure to non-ideal conditions.

Compounded liquid formulations of LDN (typically 1 mg/mL) have been shown to retain greater than 90% potency when stored in the dark at room temperature (25°C) for at least 30 days, and for up to 90 days at refrigerated temperatures (4°C) [3]. A more recent stability study by Cote et al. (2018) examined low-dose naltrexone capsules compounded in Avicel (microcrystalline cellulose) and found that these remained within 90–110% of labeled potency for a full 360 days when stored at room temperature and protected from light [4]. Similarly, Ghimire et al. (2019) demonstrated physicochemical stability of naltrexone solutions in SuspendIt vehicle for 180 days at both refrigerated and room temperature [5].

Clinical pearl: Store compounded liquid LDN in amber bottles, away from direct sunlight, ideally in a refrigerator. Capsule formulations generally have longer shelf lives than liquids. Freezing is not necessary and is far less detrimental than leaving LDN in a hot car or on a sunlit windowsill.

2. Individualized LDN Dosing

There is no universal dose of LDN. While the most commonly cited dose in the research literature is 4.5 mg at bedtime, this should be considered a midpoint rather than a target [2, 6]. The optimal dose varies substantially depending on the patient’s underlying condition, sensitivity profile, body composition, and concurrent medications.

For patients who are chemically sensitive—including many with mast cell activation syndrome (MCAS), chronic fatigue syndrome, or fibromyalgia—starting doses as low as 0.25 mg or even microgram-level doses may be necessary. Rapid dose escalation in these populations can provoke symptom flares or paradoxical worsening rather than the intended immunomodulatory benefit.

It is noteworthy that certain conditions may require doses at the higher end of the LDN range. Peripheral neuropathy, for example, may respond better to doses of 4.5 mg or higher. Srinivasan et al. (2021) demonstrated in a randomized crossover trial that LDN at 2–4 mg daily showed comparable analgesic efficacy to amitriptyline in painful diabetic neuropathy, with a notably superior safety profile [7]. D’Souza et al. (2023) further reported that neuropathic pain diagnoses, including complex regional pain syndrome, were significantly more responsive to LDN than spondylotic pain in a large retrospective case series [8].

Clinical pearl: Start low, go slow—but do not be afraid to titrate upward. Dosing is an art as much as a science, and the “right” dose is the one at which the patient achieves meaningful symptom improvement with tolerable side effects.

3. Treating Multiple Conditions with LDN

Patients rarely present with a single diagnosis. In integrative practice, it is common to encounter individuals managing multiple overlapping conditions—fibromyalgia with interstitial cystitis, neuropathy with chronic fatigue, or autoimmune disease with mood disturbances. When LDN is being considered across several conditions, a practical approach is to prioritize the most severe or functionally limiting condition first.

I often counsel patients to “engage one dragon at a time.” Attempting to address every condition simultaneously with dose adjustments, supplement changes, and lifestyle modifications creates noise that makes it impossible to determine what is actually working. For example, in a patient with both peripheral neuropathy and interstitial cystitis (IC), the IC may demand initial priority due to the severity of bladder-related pain and its profound impact on sleep and daily function. IC affects an estimated 2.7–6.5% of women in the United States, and there is substantial overlap between IC and conditions like fibromyalgia and chronic pelvic pain [9]. Clinical trials are actively investigating LDN for IC, including a Stanford University randomized placebo-controlled trial (NCT04450316) and a St. Louis University trial (NCT04313972) [9, 10].

4. Understanding Response Variability

Based on extensive clinical experience prescribing LDN across a wide range of conditions, I have observed a general distribution of treatment responses that follows roughly a rule of thirds:

• Approximately one-third of patients respond dramatically—experiencing meaningful, often life-changing improvements in pain, fatigue, or other primary symptoms within the first 2–3 months.
• Approximately one-third require dose adjustments—these patients show partial or delayed responses and may need titration, timing changes (morning versus bedtime dosing), or formulation changes (capsules versus liquid) to achieve benefit.
• Approximately one-third respond minimally—for these patients, LDN may not be the right tool, or there may be confounding factors (untreated infections, hormonal imbalances, sleep disorders) that must be addressed before LDN can exert its effects.

This distribution is broadly consistent with published literature. Younger et al. (2009) demonstrated a greater than 30% symptom reduction in fibromyalgia patients treated with LDN compared to placebo, while noting that baseline erythrocyte sedimentation rate (ESR)—an indicator of systemic inflammation—predicted over 80% of the variance in drug response [11]. This finding suggests that patients with a higher inflammatory burden may derive the greatest benefit from LDN, aligning with its proposed mechanism as a TLR4 antagonist and glial cell modulator [2]. A 2024 systematic review and meta-analysis of RCTs confirmed that LDN significantly reduced pain scores in fibromyalgia patients compared to placebo (MD: −0.86; 95% CI: −1.20, −0.51; P < 0.001) [12].

5. Conditions Potentially Helped by LDN

The range of conditions for which LDN has shown preliminary benefit continues to expand. The common thread among these conditions is the involvement of neuroinflammation, immune dysregulation, or both. The following conditions have the strongest clinical and/or research support:

Interstitial cystitis (IC/bladder pain syndrome): IC is characterized by chronic urinary urgency, frequency, and pelvic pain in the absence of infection. Emerging evidence, including active clinical trials, supports the investigation of LDN as a novel anti-inflammatory approach for IC [9, 10]. LDN’s mechanism of modulating toll-like receptor 4 (TLR4) signaling is particularly relevant here, as TLR4 has been implicated in the pathogenesis of bladder inflammation [13].

Fibromyalgia: This is the most extensively studied indication for LDN. Multiple clinical trials have demonstrated significant pain reduction, including a landmark crossover trial by Younger et al. (2013) showing a 28.8% reduction in pain versus 18.0% for placebo (P = 0.016) [6]. A 2023 systematic review affirmed that LDN appears safe and effective across the included studies, though heterogeneity in study designs limits direct comparisons [14].

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A retrospective study of 218 ME/CFS patients treated with LDN found that 73.9% reported a positive treatment response, with most experiencing improved alertness and physical and cognitive performance [15]. Mechanistic research by Cabanas et al. (2021) demonstrated that naltrexone restored impaired TRPM3 ion channel function in natural killer cells from ME/CFS patients, providing a plausible biological basis for clinical benefit [16].

Peripheral neuropathy: As noted above, LDN has shown promise in both diabetic and cryptogenic small fiber neuropathy [7, 8]. Its dual mechanism—TLR4 antagonism reducing neuroinflammation and transient opioid blockade upregulating endogenous endorphin signaling—makes it particularly well-suited for neuropathic pain conditions.

Autoimmune diseases involving Th1/Th17 immune activation: Conditions characterized by a Th1/Th17-dominant immune profile, including multiple sclerosis, Crohn’s disease, and rheumatoid arthritis, have shown responsiveness to LDN in various published studies [1, 2]. LDN’s immunomodulatory effect appears to shift the immune balance toward a more regulated state, though large-scale RCTs in many of these conditions are still needed.

6. The Multifactorial Nature of Chronic Fatigue Syndrome

While LDN can be a valuable tool in the management of CFS/ME, it is essential to recognize that CFS is not a single disease with a single solution. Rather, CFS is a multifactorial condition that may involve a constellation of contributing factors, each of which must be identified and addressed for optimal outcomes:

Sleep disorders are nearly universal in CFS/ME and often include non-restorative sleep, circadian rhythm disruption, and comorbid sleep apnea. Hormonal imbalances—particularly involving the hypothalamic-pituitary-adrenal (HPA) axis, thyroid, and sex hormones—frequently contribute to fatigue persistence. Hidden infections, including reactivated Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), Mycoplasma species, and Lyme disease, may serve as ongoing immune triggers. Nutritional deficiencies—especially iron, B12, vitamin D, magnesium, and coenzyme Q10—are commonly overlooked yet readily correctable contributors. Finally, autoimmune and endocrine dysfunction, including subclinical hypothyroidism and adrenal insufficiency, must be systematically ruled out or addressed [17, 18].

Clinical pearl: LDN is one layer of a comprehensive treatment strategy for CFS/ME. Prescribing LDN without investigating and addressing the underlying contributors is analogous to painting over rust—the surface may improve temporarily, but the structural problem persists.

7. Navigating Opioid Use with LDN

The most critical pharmacologic consideration when prescribing LDN is the concurrent use of opioid medications. Because naltrexone is a potent opioid receptor antagonist—even at low doses—administration of standard LDN doses (1–5 mg) to patients taking opioids can precipitate acute withdrawal, a potentially dangerous and deeply unpleasant event [1, 2].

When LDN is clinically indicated for a patient on chronic opioid therapy, the approach must be extremely cautious. Starting doses should be in the microgram range—not milligrams. The concept of ultra-low-dose naltrexone (ULDN), which operates in the microgram to picogram range, offers a potential pathway. Preclinical and early clinical data suggest that ULDN may actually potentiate opioid analgesia by modulating opioid receptor–G-protein coupling through interactions with filamin A, a scaffolding protein involved in mu-opioid receptor signaling [1, 19]. In a Phase II trial of Oxytrex (oxycodone combined with ultra-low-dose naltrexone), the combination produced significantly greater pain reduction than oxycodone alone or placebo in osteoarthritis patients [19].

Clinical pearl: Never initiate standard-dose LDN in a patient actively taking opioids without first reducing the opioid to the lowest feasible dose or eliminating it. If the clinical scenario requires concurrent use, start at microgram doses under close supervision. This is an area where clinical experience and careful titration are paramount—there is no reliable protocol that can substitute for individualized physician judgment.

8. The Role of Patient Education and Community

One of the greatest barriers to LDN access is not the medication itself—which is inexpensive, well-tolerated, and readily compounded—but rather the lack of awareness among prescribers. Many physicians remain unfamiliar with LDN’s mechanism of action, clinical evidence, or practical prescribing considerations. Patients often find themselves in the position of educating their own doctors, which can be frustrating and counterproductive if not handled thoughtfully.

I encourage patients to approach these conversations as collaborative partners rather than adversaries. Sharing peer-reviewed literature, well-sourced educational summaries, and clinical guidelines can open doors that confrontation cannot. Physicians are far more receptive to a patient who says, “I came across some published research I’d like to discuss with you” than one who demands a specific prescription.

The LDN Support Group, a community of over 7,000 members, serves as a resource for patients navigating these challenges. Through shared experiences, educational materials, and clinician-moderated discussions, the community helps demystify LDN and empowers patients to advocate effectively for their care. Participation in such communities can be profoundly validating for patients who have often felt dismissed or unheard by the conventional medical system.

Conclusion

Low-dose naltrexone occupies a unique position in integrative medicine: it is inexpensive, well-tolerated, mechanistically plausible, and supported by a growing—though still developing—evidence base. The practical considerations discussed in this article—stability and storage, individualized dosing, multi-condition management, response variability, opioid co-administration, and patient education—are the questions that arise daily in clinical practice and that published trials often leave unanswered.

As the research continues to mature, with large-scale randomized controlled trials now underway in fibromyalgia, interstitial cystitis, and post-COVID fatigue syndrome, we can anticipate a more robust evidence base in the coming years. Until then, the judicious, individualized use of LDN—guided by clinical experience, patient partnership, and a commitment to “engage one dragon at a time”—remains a valuable tool in the integrative practitioner’s armamentarium.

References

1. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938.
2. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250.
3. Fawcett JP, Morgan NC, Woods DJ. Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone. Ann Pharmacother. 1997;31(11):1291–1295. PMID: 9391680.
4. Cote B, Ross B, Fortner J, Rao D. The use and utility of low-dose naltrexone capsules for patients with fibromyalgia. Int J Pharm Compd. 2018;22(3):252–256. PMID: 29878893.
5. Ghimire S, Siddiqui R, Gaudette F, et al. Physicochemical stability of compounded naltrexone hydrochloride solutions in PCCA Base SuspendIt. Int J Pharm Compd. 2019;23(2):170–176. PMID: 31085781.
6. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310.
7. Srinivasan A, Dutta P, Bansal D, Bhansali A, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770–778. doi:10.1111/1753-0407.13202. PMID: 34014028.
8. D’Souza RS, Barman R, Joseph A, Salas-Vega AE. Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series. J Pain Res. 2023;16:2091–2101. doi:10.2147/JPR.S412420. PMC: 10276990.
9. ClinicalTrials.gov. Low-dose naltrexone for bladder pain syndrome: a randomized placebo-controlled prospective pilot trial. Identifier: NCT04450316. Stanford University.
10. ClinicalTrials.gov. IC PaIN Trial: Interstitial cystitis pain improvement with naltrexone. Identifier: NCT04313972. St. Louis University.
11. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963.
12. Khairani AF, et al. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean J Pain. 2024;37(4):313–323. doi:10.3344/kjp.24209. PMID: 39344363.
13. Parada CA, Bhatt DK, De Oliveira MG, et al. (cited in NCT04313972 protocol). Role of TLR4 in cyclophosphamide-induced cystitis models. Am J Physiol Renal Physiol. 2018;315(1):F90–F98.
14. Deshpande MA, Geng T, Goh FQ, et al. The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: a systematic review. Cureus. 2023;15(3):e36608. doi:10.7759/cureus.36608. PMC: 10039621.
15. Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomed Health Behav. 2019;7(4):207–217. doi:10.1080/21641846.2019.1692770.
16. Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. 2021;12:687806. doi:10.3389/fimmu.2021.687806. PMC: 8313851.
17. Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13(1):e232502. doi:10.1136/bcr-2019-232502. PMID: 31911410.
18. O’Boyle S, Nacul L, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia. BMJ Open. 2024;14(5):e078650. doi:10.1136/bmjopen-2023-078650. PMC: 11097836.
19. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Bhatt R. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005;6(6):392–399. doi:10.1016/j.jpain.2005.01.356. PMID: 15943961.

© 2026 Yoon Hang Kim, MD, MPH. All rights reserved.

Direct Integrative Care • www.directintegrativecare.com